6514 related articles for article (PubMed ID: 2738896)
1. Mono and bis(bioreductive) alkylating agents: synthesis and antitumor activities in a B16 melanoma model.
Witiak DT; Loper JT; Ananthan S; Almerico AM; Verhoef VL; Filppi JA
J Med Chem; 1989 Jul; 32(7):1636-42. PubMed ID: 2738896
[TBL] [Abstract][Full Text] [Related]
2. The contribution of alkylation to the activity of quinone antitumor agents.
Begleiter A
Can J Physiol Pharmacol; 1986 May; 64(5):581-5. PubMed ID: 3730943
[TBL] [Abstract][Full Text] [Related]
3. 2- and 6-methyl-1,4-naphthoquinone derivatives and potential bioreductive alkylating agents.
Antonini I; Lin TS; Cosby LA; Dai YR; Sartorelli AC
J Med Chem; 1982 Jun; 25(6):730-5. PubMed ID: 7097727
[TBL] [Abstract][Full Text] [Related]
4. Bis(bioreductive) alkylating agents: synthesis and biological activity in a nude mouse human carcinoma model.
Witiak DT; Kamat PL; Allison DL; Liebowitz SM; Glaser R; Holliday JE; Moeschberger ML; Schaller JP
J Med Chem; 1983 Dec; 26(12):1679-86. PubMed ID: 6685770
[TBL] [Abstract][Full Text] [Related]
5. Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines.
Beall HD; Murphy AM; Siegel D; Hargreaves RH; Butler J; Ross D
Mol Pharmacol; 1995 Sep; 48(3):499-504. PubMed ID: 7565631
[TBL] [Abstract][Full Text] [Related]
6. Potential bioreductive alkylating agents. 1. Benzoquinone derivatives.
Lin AJ; Cosby LA; Shansky CW; Sartorelli AC
J Med Chem; 1972 Dec; 15(12):1247-52. PubMed ID: 4635968
[No Abstract] [Full Text] [Related]
7. Activity of quinone alkylating agents in quinone-resistant cells.
Begleiter A; Leith MK
Cancer Res; 1990 May; 50(10):2872-6. PubMed ID: 1692249
[TBL] [Abstract][Full Text] [Related]
8. 2-Methylanthraquinone derivatives as potential bioreductive alkylating agents.
Lin TS; Teicher BA; Sartorelli AC
J Med Chem; 1980 Nov; 23(11):1237-42. PubMed ID: 7452674
[TBL] [Abstract][Full Text] [Related]
9. Naturally occurring quinones as potential bioreductive alkylating agents.
Moore HW; Czerniak R
Med Res Rev; 1981; 1(3):249-80. PubMed ID: 6810039
[No Abstract] [Full Text] [Related]
10. Potential bioreductive alkylating agents. 4. Inhibition of coenzyme Q enzyme systems by lipoidal benzoquinone and naphthoquinone derivatives.
Lin AJ; Pardini RS; Lillis BJ; Sartorelli AC
J Med Chem; 1974 Jul; 17(7):688-7. PubMed ID: 4151966
[No Abstract] [Full Text] [Related]
11. Cellular pharmacology of quinone bioreductive alkylating agents.
Rockwell S; Sartorelli AC; Tomasz M; Kennedy KA
Cancer Metastasis Rev; 1993 Jun; 12(2):165-76. PubMed ID: 8375019
[TBL] [Abstract][Full Text] [Related]
12. Potential bioreductive alkylating agents. 3. Synthesis and antineoplastic activity of acetoxymethyl and corresponding ethyl carbamate derivatives of benzoquinones.
Lin AJ; Shansky CW; Sartorelli AC
J Med Chem; 1974 May; 17(5):558-61. PubMed ID: 4830263
[No Abstract] [Full Text] [Related]
13. Modifications of cardiac contractility by redox cycling alkylating and mixed redox cycling/alkylating quinones.
Floreani M; Carpenedo F
J Pharmacol Exp Ther; 1991 Jan; 256(1):243-8. PubMed ID: 1846415
[TBL] [Abstract][Full Text] [Related]
14. Electrochemistry of potential bioreductive alkylating quinones: its use in the development of new aziridinylquinones.
Driebergen RJ; Holthuis JJ; Hulshoff A; Postma-Kelder SJ; Verboom W; Reinhoudt DN; Lelieveld P
Anticancer Res; 1986; 6(4):605-19. PubMed ID: 3752941
[TBL] [Abstract][Full Text] [Related]
15. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms for the modulation of alkylating activity by the quinone group in quinone alkylating agents.
Begleiter A; Leith MK; Pan SS
Mol Pharmacol; 1991 Sep; 40(3):454-8. PubMed ID: 1896030
[TBL] [Abstract][Full Text] [Related]
17. Studies on the mechanism of action of quinone antitumor agents.
Begleiter A
Biochem Pharmacol; 1985 Aug; 34(15):2629-36. PubMed ID: 4015705
[TBL] [Abstract][Full Text] [Related]
18. 1,3-Dialkyl-3-acyltriazenes, a novel class of antineoplastic alkylating agents.
Smith RH; Scudiero DA; Michejda CJ
J Med Chem; 1990 Sep; 33(9):2579-83. PubMed ID: 2391696
[TBL] [Abstract][Full Text] [Related]
19. Effects of L-2-oxothiazolidine-4-carboxylate on the cytotoxic activity and toxicity of cyclophosphamide in mice bearing B16F10 melanoma liver metastases.
del Olmo M; Alonso-Varona A; Castro B; Calle Y; Bilbao P; Palomares T
Melanoma Res; 2000 Apr; 10(2):103-12. PubMed ID: 10803710
[TBL] [Abstract][Full Text] [Related]
20. Potential bioreductive alkylating agents. 5. Antineoplastic activity of quinoline-5,8-diones, naphthazarins, and naphthoquinones.
Lin AJ; Lillis BJ; Sartorelli AC
J Med Chem; 1975 Sep; 18(9):917-21. PubMed ID: 1159713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
